All lobbying filings

THE MCMANUS GROUP

Lobbying for ALNYLAM PHARMACEUTICALS · Biopharmaceutical company

Filing 3rd Quarter - Termination

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · House · Senate · $20,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 1

HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 1

Medicare/Medicaid

Support for H.R. 1672 - Maintaining Investments in New Innovation Act Issues related to access and coverage in Medicare program. Implementation of provisions included in Subtitle B of PL. 117-169-Infation Reduction Act of 2022

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.